Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sera PrognosticsSERA -5.96%69 FCF Margin % is -62,728.57% as of Mar. 2026. GuruFocus rates SERA with a GF Score™ of 69/100 and a GF Value™ of $1.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Sera Prognostics ranks worse than 99.51% on this metric.
The historical rank and industry rank for Sera Prognostics's FCF Margin % or its related term are showing as below:
SERA'
s FCF Margin % Range Over the Past 10 Years
Min: -68068 Med: -32529.63 Max: -8926.8
Current: -48377.19
During the past 7 years, the highest FCF Margin % of Sera Prognostics was -8926.80%. The lowest was -68068.00%. And the median was -32529.63%.
SERA's FCF Margin % is ranked worse than 99.51% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.56
vs SERA: -48377.19
Sera Prognostics FCF Margin % Related Terms
Sera Prognostics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Sera Prognostics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sera Prognostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sera Prognostics FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics (SERA) has a FCF Margin % of -62,728.57% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sera Prognostics and its competitors. According to the industry distribution chart, Sera Prognostics ranks #811 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 99.5%.
Is Sera Prognostics' FCF Margin % too high?
Sera Prognostics' current FCF Margin % is -62,728.57%. Based on the distribution chart, Sera Prognostics ranks #811 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sera Prognostics has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' FCF Margin % compare to LNSR and ECOR?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #811 out of 815 companies for FCF Margin %. This places Sera Prognostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sera Prognostics and its competitors. Sera Prognostics's current FCF Margin % is -62,728.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $2.05 — trading 12% above its estimated fair value. The current FCF Margin % is -62,728.57%. Sera Prognostics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sera Prognostics (SERA), the current FCF Margin % is -62,728.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sera Prognostics (SERA) Overvalued in 2026?
Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued.
The current stock price of $2.05 is trading 12% above its estimated GF Value™ of $1.83.
GuruFocus considers Sera Prognostics to be Modestly Overvalued.
Key valuation signals for SERA:
FCF Margin %: -62,728.57%
GF Value™: $1.83 vs. price of $2.05 (12% above fair value)
No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
69GF Score
Get the complete analysis for SERA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SERA has been successfully added to your 
